Kenneth Howard

Associate Professor

Aarhus University

Denmark

Research Interests

Explore related searches

Professors in Immunology

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Kenneth Howard is an Associate Professor at Aarhus University in Denmark. His research focuses on biomolecular assemblies and drug designs, particularly in the context of cancer immunotherapy and the development of therapeutic agents, as evidenced by his recent publications. His work includes innovative approaches to enhance the delivery and effectiveness of antisense therapeutics and bispecific T-cell engagers through albumin-based systems.

Articles (11)

Year:

2024

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (9)

Jesper Wengel

Professor

University of Southern Denmark

DENMARK

View details

James Baker

University College London

UNITED KINGDOM

View details

Laura Creemers

Associate professor

Universitair Medisch Centrum Utrecht

NETHERLANDS

View details

Johan Palmfeldt

Associate Professor

Aarhus University

DENMARK

View details

Marwa Elkhashab

Aarhus University

DENMARK

View details

Karina Dalsgaard Sørensen

Aarhus University

DENMARK

View details

Jan Terje Andersen

University of Oslo

NORWAY

View details

Vijay Chudasama

University College London

UNITED KINGDOM

View details

Paul vinu Salachan

Aarhus University

DENMARK

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kenneth Howard

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

A Modular Albumin-Oligonucleotide Biomolecular Assembly for Delivery of Antisense Therapeutics

Albumin Biomolecular Drug Designs Stabilized through Improved Thiol Conjugation and a Modular Locked Nucleic Acid Functionalized Assembly

Identification of a high-risk immunogenic prostate cancer patient subset as candidates for T-cell engager immunotherapy and the introduction of a novel albumin-fused anti-CD3 × anti-PSMA bispecific design

An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension

Functionalized Acyclic (l)‐Threoninol Nucleic Acid Four‐Way Junction with High Stability In Vitro and In Vivo

Functionalized Acyclic (l)‐Threoninol Nucleic Acid Four‐Way Junction with High Stability In Vitro and In Vivo

Bioengineered solutions to improve cancer immunotherapies

Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity

Albumin-based drug designs for pharmacokinetic modulation

FcRn overexpression in human cancer drives albumin recycling and cell growth; a mechanistic basis for exploitation in targeted albumin-drug designs

Regulation of Gdf5 expression in joint remodelling, repair and osteoarthritis

Collaborators (9)

Jesper Wengel

James Baker

Laura Creemers

Johan Palmfeldt

Marwa Elkhashab

Karina Dalsgaard Sørensen

Jan Terje Andersen

Vijay Chudasama

Paul vinu Salachan

Make your next move.